Estrella Immunopharma, Inc. (NASDAQ:ESLA) Shares Shorted: Short Interest Up 180.2% in October

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 599,647 shares, an increase of 180.2% from the September 30th total of 214,030 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 7,569,648 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. purchased a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned about 0.12% of Estrella Immunopharma at the end of the most recent quarter. 0.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Estrella Immunopharma Stock Performance

Estrella Immunopharma stock traded down $0.09 during mid-day trading on Thursday, hitting $0.73. 270,200 shares of the company traded hands, compared to its average volume of 627,706. The stock has a fifty day moving average price of $0.59 and a 200-day moving average price of $0.99. The stock has a market cap of $31.70 million, a price-to-earnings ratio of -3.04 and a beta of 0.93. Estrella Immunopharma has a one year low of $0.24 and a one year high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. Sell-side analysts predict that Estrella Immunopharma will post -0.25 EPS for the current year.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells.

Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.

Estrella became a publicly traded company through a business combination with TradeUP Global Corporation.